

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
23 December 2021 (23.12.2021)



(10) International Publication Number
WO 2021/255155 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) A61K 39/395 (2006.01)
C07K 16/30 (2006.01) A61P 35/00 (2006.01)
C07K 16/46 (2006.01)

(21) International Application Number:

PCT/EP2021/066366

(22) International Filing Date:

17 June 2021 (17.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20181056.1 19 June 2020 (19.06.2020) EP

(71) Applicant (for all designated States except US): **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH).

(71) Applicant (for US only): **HOFFMANN-LA ROCHE INC.** [US/US]; Overlook at Great Notch, 150 Clove Road 8th Floor, Suite 8 - Legal Department, Little Falls, New Jersey 07424 (US).

(72) Inventors: **FREIMOSER-GRUNDSCHÖBER, Anne**; c/o Roche Glycart AG Wagistrasse 10, 8952 Schlieren (CH). **GONZALEZ NICOLINI, Maria, Valeria**; c/o Roche Glycart AG Wagistrasse 10, 8952 Schlieren (CH). **HOSSE, Ralf**; c/o Roche Glycart AG Wagistrasse 10, 8952 Schlieren (CH). **KLEIN, Christian**; c/o Roche Glycart AG Wagistrasse 10, 8952 Schlieren (CH). **KNAUPP, Alexander**; c/o Roche Diagnostics GmbH Nonnenwald 2, 82377 Penzberg (DE). **MOESSNER, Ekkehard**; c/o Roche Glycart AG Wagistrasse 10, 8952 Schlieren (CH). **RICHTER, Wolfgang**; c/o F. Hoffmann-La Roche AG Grenzacherstrasse 124, 4070 Basel (CH). **TROCHANOWSKA, Halina**; c/o Roche Glycart AG Wagistrasse 10, 8952 Schlieren (CH). **UMAÑA, Pablo**; c/o Roche Glycart AG Wagistrasse 10, 8952 Schlieren (CH). **WALDHAUER, Inja**; c/o Roche Glycart AG Wagistrasse 10, 8952 Schlieren (CH).

(74) Agent: **CUENI, Leah** et al.; Grenzacherstrasse 124, 4070 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,

NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: ANTIBODIES BINDING TO CD3 AND CD19

(57) Abstract: The present invention generally relates to antibodies that bind to CD3 and CD19, e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

WO 2021/255155 A1